GUANGZHOU, Aug. 29 (Xinhua): A recombinant Covid-19 fusion protein vaccine (V-01) developed and manufactured in China has been approved for phase-III clinical trials in the Philippines.
The vaccine V-01 was developed by the Institute of Biophysics under the Chinese Academy of Sciences and Livzon Pharmaceutical Group Inc. (LivzonBio) in south China's Guangdong Province.
Already a subscriber? Log in.
Subscribe now for a chance to win your dream holiday!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
